Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.

Jarushka Naidoo,Scott Antonia,Yi-Long Wu,Byoung Chul Cho,Piruntha Thiyagarajah,Helen Mann,Michael Newton,Corinne Faivre-Finn

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer（2023）

引用 7|浏览26

暂无评分

摘要

PFS and OS outcomes with durvalumab were similar to placebo for patients with EGFRm tumors, with wide CIs. These data should be interpreted with caution owing to small patient numbers and lack of a prospective study that evaluates clinical outcomes by tumor biomarker status. Further research to determine the optimal treatment for unresectable stage III EGFRm NSCLC is warranted.

查看译文

关键词

Chemoradiotherapy,Durvalumab,EGFR,NSCLC

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要